An open-label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome

Oral Surgery Oral Medicine Oral Pathology Oral Radiology and EndodontologyPublished 1 November 1998

Miriam Grushka, Joel B. Epstein, April E. Mott

Citations169

TL;DR

The results suggest that clonazepam may be helpful in burning mouth syndrome, inasmuch as 70% of patients (groups 1 and 2) experienced pain reduction with effects at low doses, and double-blind, placebo-controlled trials are warranted.

Abstract

The results suggest that clonazepam may be helpful in burning mouth syndrome, inasmuch as 70% of patients (groups 1 and 2) experienced pain reduction with effects at low doses. These findings suggest that the mechanism of action of clonazepam may be specific and separate from the anxiolytic effect of the benzodiazepines and that clonazepam may represent a useful therapy in a subset of patients with burning mouth syndrome. Double-blind, placebo-controlled trials are warranted.

Keywords

Medicine

BMJAnticonvulsant drugs for management of pain: a systematic review

718 Citations1995HJ McQuay, Dawn Carroll +3 more

Systematic review of randomised controlled trials of anticonvulsants for acute, chronic, or cancer pain identified by using Medline, by hand searching, by searching reference lists, and by contacting investigators found anticonVulsants were effective for trigeminal neuralgia and diabetic neuropathy and for migraine prophylaxis.

Oral Surgery Oral Medicine Oral PathologyClinical features of burning mouth syndrome

370 Citations1987Miriam Grushka

Those features which distinguish BMS subjects from age- and sex-matched control subjects but provide no confirmatory evidence for many of the etiologic factors frequently suggested for BMS are demonstrated.

B.C. Decker eBooksPrinciples of medical pharmacology

308 Citations1989H. Kalant, Walter H. E. Roschlau

Medicina oral, patología oral y cirugía bucalBurning mouth syndrome: An update

292 Citations2010Pía López‐Jornet, Fabio Camacho‐Alonso +3 more

This study reviews the literature on this syndrome, with special reference to the etiological factors that may be involved and the clinical aspects they present, and the diagnostic criteria that should be followed and the therapeutic management are discussed.

View PDF

PainThe analgesic effect of amitriptyline on chronic facial pain

223 Citations1987Yair Sharav, Elyse J. Singer +3 more

It appears that tricyclic antidepressants act in a fashion different from opiate drugs that alter the sensory discriminative component of pain.

Oral Surgery Oral Medicine Oral PathologyClinical characteristics and management outcome in the burning mouth syndrome

165 Citations1991Meir Gorsky, Sol Silverman +1 more

From the data BMS appears to be a chronic condition with variations in symptoms among patients and without a predictable endpoint, and it is assumed that the most effective management was in response to mood-altering drugs.

Journal of neurosurgeryNeuronal hyperactivity in experimental trigeminal deafferentation

152 Citations1971Lloyd S. Anderson, Richard G. Black +2 more

The authors postulate that brain-stem neuronal hyperactivity similar to epileptic activity is the physiological corre...

The Journal of the American Dental AssociationBurning Mouth Syndrome: An Update

140 Citations1995Jonathan A. Ship, Miriam Grushka +4 more

While patients with symptoms of BMS are more likely to seek care from physicians, dentists should be involved in the evaluation and management of these patients.

PainThe burning mouth syndrome remains an enigma

103 Citations1995Joanna M. Zakrzewska

The patient who presents with a burning mouth is a challenge to all clinicians both medical and dental as too little carefully controlled research both on aetiological factors and management has been carried out.

PubMedAdministration of clonazepam in the treatment of TMD and associated myofascial pain: a double-blind pilot study.

99 Citations1991Stephen J. Harkins, Jennifer Linford +3 more

A double-blind pilot study was undertaken to test the administration of low doses of the long-acting benzodiazepine drug clonazepam in the management of chronic intractable temporomandibular disorder/myofascial pain patients who were not responsive to occlusal splint, behavioral, and physical therapy.